Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weon Kim has a total of 587 co-authors. Here are the top co-authors by number of shared publications:

  • Jong Shin Woo

    Kyung Hee University College of Medicine: Kyung Hee University School of Medicine

    29 shared publications
  • Kyung Hye Lee

    Department of Internal Medicine, Division of Cardiovascular, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea

    16 shared publications
  • Myung Ho Jeong

    Department of Cardiology, Chonnam National University Medical School, Gwangju, Korea

    14 shared publications
  • Xian Wu Cheng

    Department of Internal Medicine, Division of Cardiovascular, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea

    13 shared publications
  • Jong Shin Woo

    Division of Cardiovascular, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, Korea

    12 shared publications
  • Haneul Cho

    Department of Internal Medicine, Division of Cardiovascular, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea

    10 shared publications

Latest Publications

  • Open Access

    Initial Antiplatelet Strategy and 1-Year Outcomes in East Asian Patients With Acute Myocardial Infarction and Renal Dysfunction

    by Seok Oh, Kyung Hoon Cho, Min Chul Kim, Doo Sun Sim, Young Joon Hong, Ju Han Kim, Jang Hoon Lee, Chang-Hwan Yoon, Weon Kim, Jin-Yong Hwang, et al.

    Oh S, et al. Korean Circ J. 2027 ;57:e17. https://doi.org/10.4070/kcj.2025.0522


  • Clopidogrel Versus Aspirin Monotherapy According to Atherothrombotic Risk Profile

    by Joo Myung Lee, Dong Hyun Gim, Yong Hwan Park, Jong-Young Lee, Jin-Ok Jeong, Chan Joon Kim, Kyeong Ho Yun, Han Cheol Lee, Kiyuk Chang, Mahn-Won Park, et al.

    BACKGROUND: Clopidogrel monotherapy has shown superior efficacy compared with aspirin after completion of dual antiplatelet therapy following percutaneous coronary intervention (PCI). However, whether treatment effects differ according to overall atherothrombotic risk integrating clinical and angiographic factors remains unclear. METHODS: This post hoc analysis of the SMART-CHOICE 3 (Smart Angioplasty Research Team: Choice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3) randomized trial included patients who completed guideline-directed dual antiplatelet therapy after PCI. Atherothrombotic risk was defined using the a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention and complex PCI. Patients with Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention ≥3 or complex PCI were classified as higher risk, and those with a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention P =0.007). In higher-risk patients, clopidogrel reduced major adverse cardiac and cerebrovascular events compared with aspirin (4.6% versus 7.4%; hazard ratio, 0.67 [95% CI, 0.50–0.89]; P =0.006), with no difference in lower-risk patients (3.0% versus 3.2%; hazard ratio, 1.03; P =0.945; interaction P =0.242). Bleeding was similar between groups. CONCLUSIONS: After completion of dual antiplatelet therapy following PCI, clopidogrel monotherapy was associated with lower ischemic risk than aspirin in patients with higher atherothrombotic risk, without increased bleeding. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04418479.

  • Restricted Loss of Life Expectancy in Patients With Acute Myocardial Infarction: A Nationwide KAMIR Registry Study

    by Jin‐Ho Choi, Ki‐Hong Choi, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Joo‐Yong Hahn, Weon Kim, Seung‐Ho Hur, Chang‐Hwan Yoon, et al.

    Background: The mortality risk of acute myocardial infarction declines rapidly after the initial period, yet the quantitative measures of residual risk in the follow‐up period remain limited. We aimed to assess restricted loss of life expectancy (LOLE) in patients with acute myocardial infarction. Methods: We included patients from KAMIR (Korea Acute Myocardial Infarction Registry), a nationwide acute myocardial infarction registry, between 2012 and 2020. The survival of 27 705 patients (mean age, 64 years; 76% men) was compared with an age‐, sex‐, and calendar year–matched reference cohort derived from Korean population life tables. Three‐year restricted LOLE was estimated using a Royston–Parmar flexible parametric survival model adjusted for clinical characteristics. Results: Overall, 3‐year restricted LOLE was 23 (95% CI, 22–25) days. In subgroup analyses, older age (≥75 years, 42 [95% CI, 37–47] days versus <50 years, 7 [95% CI, 3–10] days), female sex (44 [95% CI, 37–51] days versus male sex, 14 [95% CI, 11–17] days), and lower left ventricular ejection fraction (≤40%; 135 [95% CI, 128–142] days versus ≥50%, 0 [−2 to 1] days) were associated with higher 3‐year restricted LOLE. Across the study period, 3‐year restricted LOLE nearly halved from 36 (95% CI, 31–41) to 16 (95% CI, 9–23) days. Conclusions: Restricted LOLE provides intuitive, patient‐centered measures of residual risk after acute myocardial infarction. It also demonstrated a significant improvements in patient outcomes over the study period.

  • Open Access

    Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT

    by Jeong Cheon Ahn, Cheol Whan Lee, Jong-Hwa Ahn, Kyung Hee Lim, Il Suk Sohn, Ki-Chul Sung, Kye Hun Kim, Jang-Ho Bae, Seung Pyo Hong, Won-Young Jang, et al.

    BACKGROUND: Although low-dose triple single-pill combination therapies show promising efficacy and safety, studies comparing them to standard-dose monotherapies remain limited. This phase III, randomized, double-blind trial evaluated the efficacy and safety of a low-dose single-pill combination of telmisartan, amlodipine, and chlorthalidone versus standard-dose telmisartan monotherapy in patients with essential hypertension. METHODS: After a 4-week placebo run-in period, 314 eligible subjects were randomized to either receive telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg or telmisartan 40 mg for 8 weeks. The primary efficacy end point was the change in mean sitting systolic blood pressure from baseline to week 8, with noninferiority assessed in the per-protocol set (PPS), followed by superiority testing in the full analysis set using a gatekeeping approach to control for type I error. RESULTS: At week 8, the combination group demonstrated significant mean sitting systolic blood pressure reduction compared with monotherapy in the per-protocol set analysis (least squares mean difference, −3.8 mm Hg [95% CI: −6.7 to −0.9]; P =0.01), establishing its noninferiority. Furthermore, the superiority of the combination therapy was confirmed in the full analysis set (LS mean difference, −4.0 mm Hg [95% CI, −6.8 to −1.3]; P P <0.01). Subgroup analyses showed consistent efficacy across clinical strata, including age and prior antihypertensive treatment. The incidence of adverse events was comparable between groups, with no serious drug-related events reported. CONCLUSIONS: Low-dose triple single-pill combination of telmisartan/amlodipine/chlorthalidone demonstrated superior BP-lowering efficacy with well-tolerated and comparable safety to standard-dose telmisartan monotherapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06348576.


  • Open Access

    LOw-Dose RAbeprazole Therapy for Reducing Gastrointestinal Events in Patients with High Bleeding Risk (LORA-HBR): A Prospective, Multicenter, Interventional Study

    by Dong Oh Kang, Cheol Ung Choi, Jang Hoon Lee, Young Joon Hong, Jung-Sun Kim, Han Cheol Lee, Jay Young Rhew, Jang Hyun Cho, Weon Kim

    Background: The widespread use of antithrombotic therapies increases bleeding risk, particularly in patients with a high bleeding risk (HBR). Although proton pump inhibitors are recommended for lowering the risk of upper gastrointestinal (UGI) bleeding, the optimal agent and dosage remain uncertain. This study evaluated the efficacy and safety of low-dose rabeprazole (LORA, 5 mg) in reducing the incidence of GI-related adverse events in HBR patients receiving chronic antithrombotic therapy. Methods: This was a prospective, multicenter, interventional study that enrolled 909 South Korean patients receiving long-term antithrombotic therapy with HBR features including age ≥70 years, dual antiplatelet therapy, combined antithrombotic regimens, and prior GI bleeding. The primary endpoint was the incidence of significant GI events, including overt/occult bleeding and symptomatic peptic ulcer disease (PUD). Secondary endpoints included study drug discontinuation owing to GI adverse events, composite cardiovascular events, and all-cause mortality. Results: No patients had significant UGI bleeding or symptomatic PUD. The median adherence rate was 92.0% (interquartile range [IQR], 87.0–95.0). Drug discontinuation owing to GI symptoms occurred in 32 patients (3.52%) at a median of 81 days (IQR, 36–119 days). GI-related adverse events were reported in 3.96%, with diarrhea, epigastric discomfort, and constipation being the most common. Non-GI bleeding and cardiovascular composite events occurred in 0.33% (n = 3) each, with all-cause mortality at 0.55% (n = 5). Conclusions: Low-dose rabeprazole was associated with reduced GI complications in patients receiving chronic antithrombotic therapy, with a favorable safety profile and high adherence. Further studies with larger and broader populations are required to confirm these findings.


  • Open Access

    Cardiometabolic Syndrome Part 1: Epidemiology, Pathophysiology, and Prevention Strategies

    by Soo Lim, You-Cheol Hwang, Jang Won Son, Seung-Hwan Lee, Chang Hee Jung, Hyun-Jin Kim, Hyunjung Lim, Sang-Ho Jo, Sang Hyun Ihm, Il Suk Sohn, et al.

    Lim S, et al. Cardiometab Syndr J. 2026 Sep;6(2):175-192. https://doi.org/10.51789/cmsj.2026.6.e25

  • Open Access

    2026 Focus Update of the 2021 Korean Society of Myocardial Infarction Expert Consensus Document on Revascularization for Acute Coronary Syndromes

    by Seung Hun Lee, Ki Hong Choi, Doyeon Hwang, Young-Hoon Jeong, Jang Hoon Lee, Soon Jun Hong, Joo-Yong Hahn, Young Joon Hong, Jang-Whan Bae, Jin Yong Hwang, et al.

    This focused update from the Korean Society of Myocardial Infarction provides consensus recommendations for revascularization in acute coronary syndrome (ACS), integrating major trial evidence since 2021 with Korean real-world practice. A multidisciplinary writing committee reviewed randomized trials, meta-analyses, and recent guidelines, and achieved consensus document. Key recommendations are as follows: 1) Cardiogenic shock: prioritize culprit-first revascularization with early reassessment; apply mechanical circulatory support selectively, guided by shock phenotype and escalation criteria rather than routine use; 2) Non-ST segment elevation ACS: use risk-stratified invasive timing with clear triggers for urgent versus early angiography; 3) Access and imaging: adopt radial-first access and broaden intravascular imaging for complex anatomy, ambiguous culprit lesions, and optimization of stent expansion; 4) Non-culprit lesion: favor complete revascularization in ST-segment elevation myocardial infarction (MI) with multivessel disease; select immediate versus staged procedures based on hemodynamics, ischemic burden, renal function, and contrast load. (5) Special scenarios: implement mechanism-based pathways for MI with non-obstructive coronary arteries and spontaneous coronary artery dissection (SCAD), incorporating intracoronary imaging, functional testing, vasospasm provocation, and cardiac magnetic resonance imaging; prefer conservative treatment for SCAD unless ongoing ischemia persists. The document provides concise "do" statements, and a summary of changes from 2021 to facilitate bedside adoption. These recommendations aim to standardize high-value, patient-centered ACS care in Korea, reduce practice variability, and improve outcomes while acknowledging areas requiring further evidence.

  • Open Access

    Clinical Outcomes and Use of Implantable Cardioverter-Defibrillator in Ischemic Heart Failure Patients with Reduced Ejection Fraction: A Retrospective Observational Study

    by Kyung Hoon Cho, Ki Hong Lee, Yong-Kyu Lee, Seok Oh, Yongwhan Lim, Joon Ho Ahn, Seung Hun Lee, Dae Young Hyun, Min Chul Kim, Doo Sun Sim, et al.

    Cho KH, et al. Chonnam Med J. 2026 May;62(2):55-63. https://doi.org/10.4068/cmj.2026.62.2.55

  • Open Access

    Antiplatelet Therapy in East Asian Patients With Acute Coronary Syndrome: Current Evidence and Evolving Strategies

    by Satoshi Honda, Young Hoon Jeong, Kyung Hoon Cho, Sang Yeub Lee, Kensaku Nishihira, Sunao Kojima, Yasuhide Asaumi, Yu Kataoka, Doo Sun Sim, Hyun Kuk Kim, et al.

    Honda S, et al. J Cardiovasc Interv. 2026 ;5:e22. https://doi.org/10.54912/jci.2025.0047

  • Open Access

    Physician Disagreement With Guidelines as a Critical Barrier to Achieving LDL-C Targets in Very High-Risk Patients: An Implementation Science Study

    by Kyung Hoon Cho, Young Rak Cho, Sang-Rok Lee, Jang-Whan Bae, Chang-Wook Nam, Yongwhi Park, Jin-Yong Hwang, Kyeong Ho Yun, Weon Kim, Min Chul Kim, et al.

    Cho KH, et al. J Korean Med Sci. 2026 Feb;41:e74. https://doi.org/10.3346/jkms.2026.41.e74